Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B-Interim Result of Post Marketing Surveillance Study

被引：0
|
作者：
Suzuki, Takashi [1 ]
Fukutake, Katsuyuki [1 ]
Amano, Kagehiro [1 ]
Hanabusa, Hideji [2 ]
Taki, Masashi [3 ]
Matsushita, Tadashi [4 ]
Shima, Midori [5 ]
Sakai, Michio [6 ]
Iizuka, Masahiro
Shibasaki, Yoshiyuki
机构：
[1] Tokyo Med Univ, Dept Lab Med, Tokyo 1608402, Japan
[2] Ogikubo Hosp, Dept Hematol & Pediat, Tokyo, Japan
[3] St Marianna Univ, Dept Pediat, Sch Med, Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan
[4] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan
[5] Nara Med Univ, Dept Pediat, Nara, Japan
[6] Univ Occupat & Environm Hlth, Dept Pediat, Fukuoka, Japan
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3378.3378
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3378
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of the safety and efficacy of recombinant Factor IX (nonacog alfa) in Japanese patients with hemophilia B - The second interim analysis of 304 patients in a post-marketing surveillance study
    Amano, Kagehiro
    Fukutake, Katsuyuki
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Shima, Midori
    Sakai, Michio
    Yamaguchi, Hiromi
    Karumori, Toshiyuki
    [J]. HAEMOPHILIA, 2014, 20 : 22 - 22
  • [2] Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with hemophilia B
    Renchi, Y.
    Zhao, Y.
    Wang, X.
    Sun, J.
    Jin, J.
    Wu, D.
    Charnigo, R.
    O'Brien, A.
    Rendo, P.
    Zhong, Z.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 356 - 356
  • [3] Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
    Fukutake, Katsuyuki
    Taki, Masashi
    Matsushita, Tadashi
    Sakai, Michio
    Takata, Ami
    Yamaguchi, Hiromi
    Karumori, Toshiyuki
    [J]. HAEMOPHILIA, 2019, 25 (04) : E247 - E256
  • [4] Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B
    Yang, R.
    Zhao, Y.
    Wang, X.
    Sun, J.
    Jin, J.
    Wu, D.
    Charnigo, R.
    O'Brien, A.
    Zhong, Z.
    Rendo, P.
    [J]. HAEMOPHILIA, 2012, 18 (05) : E374 - E378
  • [5] A prospective post-authorization safety surveillance study in Japanese hemophilia B patients with recombinant factor IX Fc fusion protein (rFIXFc)
    Hanabusa, Hideji
    Higasa, Satoshi
    Taki, Masashi
    Kobayashi, Masao
    Hashizume, Akio
    Makioka, Haruki
    Shiraishi, Mutsumi
    Hirakata, Toshiyuki
    [J]. HAEMOPHILIA, 2016, 22 : 52 - 52
  • [6] Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients
    Rendo, Pablo
    Berntorp, Erik
    Keeling, David M.
    Makris, Michael
    Hermans, Cedric R.
    Mauser-Bunschosten, Ereline Pauline
    Musso, Roberto
    Tagliaferri, Annarita
    Kollmer, Carl
    Baumann, James
    Charnigo, Robert
    [J]. BLOOD, 2010, 116 (21) : 1504 - 1504
  • [7] SAFETY OF BeneFIX® (NONACOG ALFA, RECOMBINANT HUMAN FACTOR IX) FOR USUAL USE IN PEDIATRIC PATIENTS: RESULTS FROM A PROSPECTIVE REGISTRY OF EUROPEAN HEMOPHILIA B PATIENTS
    Rendo, Pablo
    Berntorp, Erik
    [J]. PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 811 - 811
  • [8] SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX FUSION PROTEIN IN PEDIATRIC PATIENTS WITH HEMOPHILIA B
    Chambost, Herve
    Drelich, Douglass
    Seifert, Wilfried
    Castaman, Giancarlo
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S175 - S175
  • [9] Population pharmacokinetic modeling of factor IX activity after administration of nonacog alfa in patients with hemophilia B
    Korth-Bradley, Joan M.
    Suzuki, Akiyuki
    Tomono, Yoshiro
    [J]. HAEMOPHILIA, 2016, 22 : 102 - 102
  • [10] Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study
    Andre Holme, Pal
    Hvitfeldt Poulsen, Lone
    Tueckmantel, Claudia
    Alvarez Roman, Maria Teresa
    De Cristofaro, Raimondo
    [J]. BLOOD, 2021, 138
12345